Evacetrapib was a drug under development by Eli Lilly & Company (investigational name LY2484595) that inhibits cholesterylester transfer protein (CETP inhibitor). CETP collects triglycerides from very low-density lipoproteins (VLDL) or low-density lipoproteins (LDL) and exchanges them for cholesteryl esters from high-density lipoproteins (HDL), and vice versa, but primarily increasing high-density lipoprotein and lowering low-density lipoprotein.
Evacetrapib evaluation for treatment of high-risk vascular disease was discontinued due to lack of efficacy, as had already happened in the past with two other CETP inhibitors (torcetrapib and dalcetrapib) due to increased deaths and little identifiable cardiovascular benefit (despite substantial increases in HDL).
Research about this drug is terminated.
Research about this drug is terminated.
Research about this drug is terminated.
Research about this drug is terminated.
Zeffix is a brand name for the medication lamivudine. It is an antiviral medication primarily used in the treatment of [...]
Xentor is a brand name for the medication atorvastatin, which belongs to a class of drugs known as statins. Statins [...]
Wolvit, also known as Biotin or Vitamin B7, is a water-soluble vitamin that plays a crucial role in various metabolic [...]
